Journal
JOURNAL OF THE AMERICAN HEART ASSOCIATION
Volume 7, Issue 17, Pages -Publisher
WILEY
DOI: 10.1161/JAHA.118.010027
Keywords
antibiotic; cardiac valvular surgery; infective endocarditis; outcome; transcatheter aortic valve implantation
Categories
Funding
- Leipzig Heart Institute
Ask authors/readers for more resources
Background-Infective endocarditis (IE) after transcatheter aortic valve replacement is a devastating complication associated with a high mortality. Our objective was to determine the impact of cardiac surgery (CS) and antibiotics (IE-CS) compared with medical treatment with antibiotics only (IE-ABx) on 1-year mortality in patients developing IE after transcatheter aortic valve replacement. Methods and Results-Patients developing IE after transcatheter aortic valve replacement were included in this retrospective analysis. All-cause 1-year mortality was the primary end point. A total of 20 patients underwent IE-CS compared with 44 patients treated by IE-ABx. In this unmatched cohort, patients treated by IE-ABx were older (P=0.006), had a higher Society of Thoracic Surgeons score (P=0.029), and more often had severe chronic kidney disease (P=0.037). One-year mortality was not different between groups (IE-CS versus IE-ABx, 65% versus 68.2%; P=0.802). The rate of any complication during treatment was higher in the IE-CS group (P=0.024). In a matched cohort, baseline characteristics were not significantly different. All-cause 1-year mortality was not different between groups (IE-CS versus IE-ABx, 65% versus 75%; P=0.490). A Cox regression analysis revealed any indication for surgery (hazard ratio, 6.20; 95% confidence interval, 1.80-21.41; P=0.004), sepsis on admission (hazard ratio, 4.03; 95% confidence interval, 1.97-8.24; P<0.001), and mitral regurgitation >= 2 (hazard ratio, 2.91; 95% confidence interval, 1.33-6.37) as factors associated with 1-year mortality. Conclusions-In patients developing IE after transcatheter aortic valve replacement, mortality was predicted by the severity of IE and concomitant mitral regurgitation. In this small, and therefore statistically limited, but high-risk patient cohort, CS provided no significant mortality benefit compared with medical therapy. Individual decision making by a heart and endocarditis team is necessary to offer those patients the most reasonable treatment option.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available